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venous systems in 46.8% of cases in the EVRA 
trial.1 A previous trial showed that foam sclero-
therapy for truncal incompetence resulted in a 
lower occlusion rate (51%) at 1 year than did 
endovenous laser ablation (97%), with up to 
54% of patients requiring additional treatment 
by 5 years.4 We propose that if thermal ablation 
had been used exclusively in the trial by Gohel 
et al., the healing rates may have been even higher 
in the intervention groups.4,5
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The authors reply: We agree that the concept 
of comparing endovenous interventions with com-
pression alone would be interesting. However, 
considering the evidence of the benefits of com-
pression with respect to leg ulcer healing, we be-
lieved that it may be regarded as unethical not to 
offer compression to patients. The study was 
therefore designed to show whether there was a 
benefit of early intervention in terms of healing, 
in light of the fact that the Effect of Surgery 
and Compression on Healing and Recurrence 
(ESCHAR) study clearly showed that recurrence 
rates were lower with compression plus surgical 
intervention than with compression alone.1
We acknowledge that ablation of the truncal 
vein by thermal ablation may result in a higher 
long-term occlusion rate than ablation by other 
means.2 However, a number of randomized 
studies have shown good results with respect to 
the use of foam treatment to enhance leg-ulcer 
healing.3,4 There is also a need to evaluate the 
potential benefit of foam sclerotherapy applied 
to the small veins in the base of the leg ulcer in 
terms of ulcer healing.
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Subclinical Hyperthyroidism
To the Editor: In their Clinical Practice article, 
Biondi and Cooper (June 21 issue)1 state that 
Graves’ disease is a common cause of endoge-
nous subclinical hyperthyroidism, accounting for 
40% of cases in populations with adequate iodine 
intake. The authors cite a review article2 that ref-
erences original articles reporting a prevalence of 
Graves’ disease that is much lower than 40% 
(<10%) among patients with subclinical hyper-
thyroidism.3 Indeed, although one study showed 
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that 4 of 10 patients with a fully suppressed thy-
rotropin level did have underlying Graves’ dis-
ease, of the 20 patients who had a persistently 
partially suppressed thyrotropin level, only 1 (5%) 
had underlying Graves’ disease.4
Graves’ disease is implicated in a small but 
clinically significant proportion of patients with 
subclinical hyperthyroidism who have a fully sup-
pressed thyrotropin level.2,4 However, only a mi-
nority of patients with a partially suppressed 
thyrotropin level have underlying Graves’ dis-
ease, and these patients are more likely to have 
underlying multinodular goiter or toxic adenoma 
than patients with a fully suppressed thyrotro-
pin level.4,5
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To the Editor: Mortality is increased among pa-
tients with hyperthyroidism, independent of the 
thyrotropin level1 and phenotype.2 In their arti-
cle on subclinical hyperthyroidism, Biondi and 
Cooper advocate treating a 65-year-old woman 
with mild subclinical hyperthyroidism (thyrotro-
pin level, 0.2 mU per liter) and some clinically 
aggravating factors. We think that this recom-
mendation can be extended far beyond their sug-
gestions.
In population-based, observational studies 
based on Danish databases and involving more 
than 230,000 patients (mean follow-up, 7 years), 
we have found an excess mortality of 36% (95% 
confidence interval [CI], 16 to 60) among pa-
tients with untreated subclinical hyperthyroid-
ism.3 In patients who received treatment and 
were followed over a similar period, no excess 
mortality was shown. In patients who received 
treatment for hypothyroidism, every 6-month pe-
riod of overtreatment (thyrotropin level <0.3 mU 
per liter) was associated with an excess mortal-
ity of 18% (95% CI, 15 to 21).4 Overall, this rate 
was independent of other preexisting conditions, 
sex, and whether the patient was younger than 
65 years of age or 65 years or older.
These data provide strong support for treat-
ment of all patients with verified subclinical 
hyperthyroidism, whether endogenous or exoge-
nous. They also underscore the necessity of main-
taining a normal thyrotropin level in patients 
during follow-up.
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To the Editor: An important consideration that is 
missing from the differential diagnosis of Biondi 
and Cooper is laboratory interference. Spurious 
values of thyroid-function tests caused by inter-
ference with laboratory assays have been report-
ed in relation to patient antibodies,1 paraproteins 
in multiple myeloma,2 and most importantly, supra-
physiologic levels of biotin.
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Biotin interferes with many common immu-
noassays.3 However, the manner in which biotin 
affects thyroid-function tests is particularly alarm-
ing, since it produces a biochemical picture 
consistent with Graves’ disease.4
The Recommended Dietary Allowance of bio-
tin, which is also labeled as vitamin H, vitamin B7, 
and coenzyme R, is 300 μg daily, but it is avail-
able commercially in doses of up to 100,000 μg. 
Patients may not report biotin use, and often they 
are unaware of its common presence in products 
for hair and nail care.
Laboratories should report not only whether 
assays are vulnerable, but also the expected pat-
tern. In order to avoid unnecessary testing, re-
ferrals, or treatment, I think clinicians should 
recommend that patients abstain from biotin 
supplements for 48 to 72 hours before a blood 
sample is obtained, or longer in patients who are 
taking megadoses of biotin or who have im-
paired renal function.
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The authors reply: Williams et al. take issue 
with the fact that we stated that 40% of patients 
with subclinical hyperthyroidism have Graves’ dis-
ease, with the remainder having toxic multinod-
ular goiter or a solitary autonomously function-
ing thyroid nodule. Although precise percentages 
of each diagnosis are difficult to glean from the 
literature, we agree with Williams et al. that 
Graves’ disease occurs in a distinct minority of 
patients, especially in those with mild subclini-
cal hyperthyroidism, in whom serum thyrotropin 
levels are not fully suppressed.
Hegedüs et al. cite their own study showing 
higher mortality among patients with untreated 
subclinical hyperthyroidism than among those 
who receive treatment.1 We did not include this 
study in our article because of the paradoxical 
nature of their findings. In their population, 
mortality among patients with untreated overt 
hyperthyroidism (hazard ratio, 1.03; 95% CI, 
0.88 to 1.20) was the same as that observed 
among patients with treated overt hyperthyroid-
ism (hazard ratio, 1.03; 95% CI, 0.93 to 1.15), 
and these rates of death were not different from 
those in the euthyroid control population. Be-
cause of space limitations, we were not able to 
describe their article fully. We cannot agree with 
their recommendation, which is based solely on 
observational data, to treat all patients with sub-
clinical hyperthyroidism. We stand by published 
clinical practice guidelines that advocate individ-
ualized treatment decisions based on the level of 
serum thyrotropin, patient age, and coexisting 
conditions.
Haddad appropriately points out that inges-
tion of biotin can cause falsely low serum thyro-
tropin levels in immunoassays using streptavidin–
biotin systems. In addition to affecting serum 
thyrotropin levels, artifactual values for free 
thyroxine, triiodothyronine (T3), free T3, prolactin, 
N-terminal pro–brain natriuretic peptide, and 
25-hydroxyvitamin D may be observed.2 Since 
clinicians do not usually know the assay system 
being used in clinical chemical laboratory tests, 
patients should avoid biotin ingestion before 
undergoing routine laboratory testing. Further-
more, as was pointed out by Haddad, there are 
a host of other causes of spurious findings in 
thyroid-function tests,3 so results require clinical 
correlation and should never be interpreted in 
isolation.
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corrections
Blood-Pressure and Cholesterol Lowering in Persons without 
Cardiovascular Disease (N Engl J Med 2016;374:2032-2043). 
The disclosure statement for Dr. Lonn (p. 2042) should have 
read, “Dr. Lonn reports receiving fees for serving on advisory 
boards from Amgen, Sanofi, Novartis, and Servier, lecture fees 
from Amgen and Sanofi, and grant support through her insti-
tution from Bayer, GlaxoSmithKline, Merck/Schering-Plough, 
Eli Lilly, and Cadila Pharmaceuticals,” rather than “Dr. Lonn 
reports receiving fees for serving on advisory boards from Am-
gen, Sanofi, Novartis, Cadila Pharmaceuticals, and Servier, lec-
ture fees from Amgen and Sanofi, and grant support through 
her institution from Bayer, GlaxoSmithKline, Merck/Schering-
Plough, and Eli Lilly.” The article is correct and the disclosure 
forms have been updated at NEJM.org.
Effects of Testosterone Treatment in Older Men (N Engl J Med 
2016;374:611-624). Corrections made in the trial database re-
vealed errors in several numbers reported in the text and tables. 
In the first sentence of the Physical Function Trial subsection 
of Results (p. 615), the parenthetical “(mean difference, 4.09 m; 
P = 0.28)” should have read, “(mean difference, 4.15 m; P = 0.25).” 
In the second sentence, the parenthetical “(odds ratio, 1.76; 
P = 0.003)” should have read, “(odds ratio, 1.77; P = 0.003).” In 
the “Men enrolled in Physical Function Trial” section of Ta-
ble 2 (p. 618), in the Testosterone row below “6-Min walking 
distance,” the value in the Month 9 column should have been 
5.5±50.3, rather than 5.3±50.3. In the same row, in the Treat-
ment Effect column, the values should have been 4.15 (−2.95 to 
11.24), rather than 4.09 (−3.00 to 11.18), and the P value on the 
far right should have been 0.25, rather than 0.28. In the “All 
Testosterone Trials participants” section of the table, in the 
Testosterone row below “Increase of ≥50 m in 6-min walk 
test,” the values in the Treatment Effect column should have 
been 1.77 (1.21 to 2.58), rather than 1.76 (1.21 to 2.57). In the 
same section of the table, in the rows below “6-Min walking 
distance” (p. 619), the Month 3 value for Testosterone should 
have been 10.0±45.1, rather than 10.9±45.1, and the Month 3 value 
for Placebo should have been 1.5±41.9, rather than 1.6±41.9. 
The article is correct at NEJM.org.
notices
Notices submitted for publication should contain a mailing 
address and telephone number of a contact person or depart-
ment. We regret that we are unable to publish all notices 
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2ND INTERNATIONAL SYMPOSIUM ON RESEARCH  
IN ACUPUNCTURE
The symposium will be held in Bologna, Italy, Oct. 20 and 21.
Contact Alessandra Ricci at segreteriascuola@amabonline.it; or 
call (39) 340-9553985; or see https://www.acupunctureresearch.eu/. 
MEDICAL SPANISH AND CULTURAL COMPETENCY 
CONFERENCE
The conference will be held in La Paz, Mexico, Oct. 19–22; 
in San Francisco, Nov. 2–5; in San Diego, CA, Nov. 16–19; in 
Phoenix, AZ, Nov. 30–Dec. 3; and in Las Vegas, Dec. 7–10.
Contact Rios Associates, 3729 N. Bay Horse Loop, Tucson, 
AZ 85719; or call (520) 907-3318; or fax (480) 772-4889; or see 
http://www.medspanish.org.
THOMAS L. PETTY ASPEN LUNG CONFERENCE
The 62nd Annual Meeting, entitled “Exploring New Thera-
peutic Pathways in Pulmonary Hypertension: Metabolism, Pro-
liferation, and Personalized Medicine,” will be held in Aspen, 
CO, June 5–8. Deadline for submission of abstracts is Feb. 14.
Contact Dr. Brian Graham, c/o Jeanne Cleary, Thomas L. 
Petty Aspen Lung Conference, P.O. Box 1622, Parker, CO 80134; 
or call (303) 358-2797; or e-mail Jeanne.Cleary@ucdenver.edu; 
or see http://www.aspenlungconference.org.
MAYO CLINIC SCOTTSDALE
The following courses will be offered in Scottsdale, AZ, un-
less otherwise indicated: “21st Annual Mayo Clinic Internal 
Medicine Update” (Oct. 25–28); “Mayo Clinic Pancreatic and 
Hepato-Biliary Cancer Symposium 2018” (Oct. 26 and 27); 
“Multidisciplinary Update in Breast Disease” (Nov. 8–10); 
“Mayo Clinic Cancer Center: Thoracic Oncology Update 2018” 
(Phoenix, AZ, Nov. 9 and 10); “Mayo Pathology Update 2019” 
(Phoenix, AZ, Jan. 24–26); “Practical Proton Therapy Seminar 
and Workshop” (Jan. 24–26); and “15th Annual Mayo Clinic 
Women’s Health Update” (Feb. 28–March 2).
Contact Mayo School of Continuous Professional Develop-
ment, Mayo Clinic, 13400 E. Shea Blvd., Scottsdale, AZ 85259; or 
call (480) 301-4580; or fax (480) 301-8323; or e-mail mca.cme@
mayo.edu; or see http://www.mayo.edu/cme.
MAYO CLINIC
The following courses will be offered in Rochester, MN, 
unless otherwise indicated: “92nd Annual Clinical Reviews 
2018” (Oct. 22–24, Nov. 5–7); “Mayo Clinic Opioid Conference: 
Evidence, Clinical Considerations and Best Practice 2018” 
(Kohler, WI, Oct. 25 and 26); “Mayo Clinic Frontiers in Addic-
tion Treatment 2018” (Nov. 2); “28th Annual Mayo Clinic Sym-
posium on Sports Medicine 2018” (Nov. 9 and 10); “Sympo-
sium on Regenerative Medicine and Surgery” (Scottsdale, AZ, 
Nov. 29–Dec. 1); “2019 Mayo Clinic Advancements in Surgical 
& Medical Management of the Spine” (Kohala Coast, HI, Jan. 
13–17); “16th Annual Mayo Clinic Hematology Review 2019” 
(Minneapolis, Jan. 19); “Psychiatry in Medical Settings 2019” 
(Sarasota, FL, Jan. 24–26); “31st Annual Selected Topics in In-
ternal Medicine” (Waikoloa, Big Island, HI, Jan. 28–Feb. 1); 
“2019 Multiple Sclerosis and Autoimmune Neurology Update” 
(Phoenix, AZ, Feb. 8 and 9); “7th Annual Acute Care of the 
Complex Hospitalized Patient for NPs & PAs” (Scottsdale, AZ, 
Feb. 13–16); “Clinical Multidisciplinary Hematology & Oncol-
ogy: the 16th Annual Review” (Scottsdale, AZ, Feb. 15–17); 
“Mayo Clinic Gastroenterology and Hepatology 2019” (Scotts-
dale, AZ, Feb. 21–24); and “Mayo Clinic Psychiatry Clinical Up-
dates 2019” (Kohala Coast, HI, Feb. 26–March 1).
Contact the Mayo School of Continuous Professional Devel-
opment, 200 First St. SW, Rochester, MN 55905; or call (800) 
323-2688 or (507) 284-2509; or fax (507) 284-0532; or see 
https://ce.mayo.edu; or e-mail cme@mayo.edu.
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